Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Sezzle Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while Sezzle Inc trades at $126.5 (market cap $4.32B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 2.2× Sezzle Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Sezzle Inc nearer its low. Which is the better fit depends on your goals.
| BIO | SEZL | |
|---|---|---|
Market Cap | $9.43B | $4.32B |
Sector | Health | Technology |
52-Week High | $362.08 | $188.55 |
52-Week Low | $241.71 | $50.97 |
Enterprise Value | $9.18B | $4.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $362.08, up 2.13% daily, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, Q2 2026 earnings beat estimates with EPS of $2.62 versus $1.75 expected, and revenue remains stable around $2.6 billion. Net income turned positive in 2025 after prior losses, with a current net margin of 29.41%. Analyst consensus is Buy with a $350 price target, and institutional holdings increased, as noted by Amundi's 1,763.4% stake growth per SEC filing on August 5, 2026.
Outlook is cautiously optimistic with solid earnings recovery and institutional support, but risks include high P/E of 43.39, potential overvaluation, and reliance on academic research markets. Investors should weigh strong profitability against valuation concerns and monitor upcoming Q3 earnings for sustained growth.
Sezzle (SEZL) trades at $125.44, up 6.31% in the past 24 hours, with a bearish technical signal but strong fundamentals including a 30.35% net income margin and consistent earnings beats. Recent Q2 2026 results showed revenue growth of 51.7% year-over-year to $149.7 million, with management raising full-year guidance for the third time in 2026, indicating robust operational momentum despite a recent stock decline.
The outlook is mixed: bullish fundamentals and analyst consensus support upside to a $158.29 price target, but technical indicators and valuation premiums pose risks. Key opportunities include subscriber growth and AI integration, while risks involve execution pressure and market volatility. Investors should weigh strong profitability against high P/E and P/S ratios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
